Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus platinum-etoposide as first-line treatment for extensive-stage small cell lung cancer
ChiCTR2100044981Phase 2Recruiting
- Sponsor
- Oncology Department of PLA General Hospital
- Start
- Apr 2021
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in small cell lung cancer (SCLC), sponsored by Oncology Department of PLA General Hospital. Primary endpoint: progression-free survival. Started Apr 2021; status: recruiting.
02
Drugs
envafolimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100044981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044981.